Literature DB >> 6625779

Total, dialyzable, and nondialyzable postabsorptive hydroxyproline. Values in patients with cancer.

H B Niell, G M Palmieri, C L Neely, T A Maxwell, S C Hopkins, M S Soloway.   

Abstract

The postabsorptive urinary total (T), dialyzable (D), and nondialyzable (ND) hydroxyproline (HYPRO) tests were evaluated to determine whether the patterns of excretion varied according to the predominance of osteoblastic v osteolytic bone involvement in 58 patients with neoplastic disease. In patients with osteolytic lesions from multiple myeloma, elevated T and D levels with normal ND HYPRO values were observed, along with elevated D/ND ratios. In prostate cancer, the T, D, and ND values were all elevated and the D/ND ratio was normal. Patients with Hodgkin's disease had elevated T, D, and ND HYPRO levels, and the D/ND ratio was in the range of patients with prostate cancer. The data suggest that these collagen markers may be useful in the long-term evaluation of these neoplasms in patients.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6625779

Source DB:  PubMed          Journal:  Arch Intern Med        ISSN: 0003-9926


  4 in total

1.  Skeletal surveys in multiple myeloma. Radiologic-clinical correlation.

Authors:  J I Sebes; H B Niell; G M Palmieri; T J Reidy
Journal:  Skeletal Radiol       Date:  1986       Impact factor: 2.199

2.  Bone morphogenetic protein 7 in dormancy and metastasis of prostate cancer stem-like cells in bone.

Authors:  Aya Kobayashi; Hiroshi Okuda; Fei Xing; Puspa R Pandey; Misako Watabe; Shigeru Hirota; Sudha K Pai; Wen Liu; Koji Fukuda; Christopher Chambers; Andrew Wilber; Kounosuke Watabe
Journal:  J Exp Med       Date:  2011-11-28       Impact factor: 14.307

3.  Comparative evaluation of markers of bone resorption in patients with breast cancer-induced osteolysis before and after bisphosphonate therapy.

Authors:  J J Body; J C Dumon; E Gineyts; P D Delmas
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

4.  Host-derived RANKL is responsible for osteolysis in a C4-2 human prostate cancer xenograft model of experimental bone metastases.

Authors:  Colm Morrissey; Paul L Kostenuik; Lisha G Brown; Robert L Vessella; Eva Corey
Journal:  BMC Cancer       Date:  2007-08-03       Impact factor: 4.430

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.